Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874471 | 0.89 | TACR3 (0.42) | EPHX2ITGB3ITGA2BEPHX1ALDH1A1 | |
| SCHEMBL15874470 | 0.89 | TACR3 (0.42) | EPHX2ITGB3ITGA2BEPHX1ALDH1A1 | |
| SCHEMBL23842029 | 0.85 | EPHX2 (0.47) | EPHX2EPHX1ALDH1A1BLMNAMPT | |
| SCHEMBL16077702 | 0.82 | EPHX2 (0.51) | EPHX2EPHX1ALDH1A1BLM | |
| SCHEMBL4487574 | 0.82 | EPHX2 (0.51) | EPHX2EPHX1ALDH1A1BLM | |
| SCHEMBL14610967 | 0.81 | ITGB3 (0.60) | ITGB3ITGA2BALDH1A1NAMPT | |
| SCHEMBL23842030 | 0.80 | EPHX2 (0.44) | EPHX2EPHX1ALDH1A1NAMPT | |
| SCHEMBL14611310 | 0.80 | ALDH1A1 (0.43) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL14610970 | 0.80 | ITGB3 (0.43) | ITGB3ITGA2BALDH1A1NAMPT | |
| SCHEMBL2422675 | 0.80 | EPHX2 (0.42) | EPHX2ITGB3ITGA2BEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| CN-102099339-A | Benzazepine derivatives and their use as hstamine h3 antagonists | 武田药品工业株式会社 | 2011-06-15 | — | — | CN | disclosed |
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | EPHX2 749/4885ITGB3 1426/4885ITGA2B 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.